Transfer to long-acting buprenorphine from full opioid agonists in different dependent demographics: do’s, don’ts, and why does it matter?
Join our autumn educational session led by Dr Michael Frost, who will be joined by Professor Michael Soyka as they discuss perspectives from both opioid-dependent treatment providers and patients surrounding the use of long-acting buprenorphine (LAB) in different treatment scenarios and treatment journey stages. They will also discuss best practice approaches for transferring patients from daily dose methadone or buprenorphine to LAB, potential transfer outcomes and next steps.
This webinar will cover:
- Perspectives/experience from professionals and patients
- Experience in different treatment scenarios (stable patients versus [at-risk of becoming/] unstable patients)
- Transfer strategies to avoid (precipitated) withdrawal – micro-dosing
- LAB treatment optimisation during the switch / transfer and throughout ongoing treatment; and options for patients who find LAB unsuitable
Register your interest now for this live free event on: 25th October 13:00 BST / 14:00 CEST
Speaker – Professor Michael Soyka
Medical Director
Psychiatric Hospital, University of Munich, Germany
Funding Statement
The IOTOD webinar ‘Transfer to long-acting buprenorphine from full opioid agonists in different dependent demographics: do’s, don’ts, and why does it matter?’ is supported by grant funding from Camurus. The educational programme is run at arm’s length from the financial supporters and all content is created by the faculty. No funder has had input into the content of the materials or presentations used in the educational programme. PCM Scientific is the medical education company acting as scientific secretariat and webinar organiser.